Literature DB >> 23507222

Establishing computed tomography-defined visceral fat area thresholds for use in obesity-related cancer research.

Suzanne L Doyle1, Anne Marie Bennett, Claire L Donohoe, Ann Marie Mongan, Julia M Howard, Fiona E Lithander, Graham P Pidgeon, John V Reynolds, Joanne Lysaght.   

Abstract

Excess visceral adiposity is associated with increased gastrointestinal cancer risk. Evidence suggests that the systemic inflammation and dysmetabolism observed in visceral obesity underpins this association. Along with magnetic resonance imaging, computed tomography is a gold standard for abdominal fat quantification and is routinely available for gastrointestinal cancer research. However, no gender-specific cutoff values are currently available for classifying visceral obesity in white populations. Using the metabolic syndrome (MetSyn) as an indicator of obesity-associated dysmetabolism, this study aimed to establish pathologically relevant, gender-specific cut-off values for use in obesity-associated cancer research. Total, visceral and subcutaneous fat areas were calculated between the L3 and L4 invertebral space from computed tomography scans in a cohort of 170 males and 66 females undergoing gastrointestinal resection. Receiver operating characteristics analysis was used to determine cut-off values for total, visceral and subcutaneous fat areas associated with MetSyn. Linear regression was used to correlate these values with waist circumference. Visceral fat area (VFA) strongly correlated with the presence of MetSyn (P < .0001). The cut-off value for VFA associated with the presence of MetSyn was 163.8 cm(2) in males (83.6% sensitivity, 62.5% specificity) and 80.1 cm(2) for females (96% sensitivity, 73.2% specificity). The waist circumference corresponding to these VFA values was 96.1 cm in males and 83.2 cm in females. This study is the first to generate gender-specific and pathologically relevant cut-off values for VFA in patients with gastrointestinal cancer. In the field of obesity-associated research, this new anthropometric measure is of paramount importance for determining the accurate pathological obesity status of cancer patients.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23507222     DOI: 10.1016/j.nutres.2012.12.007

Source DB:  PubMed          Journal:  Nutr Res        ISSN: 0271-5317            Impact factor:   3.315


  33 in total

1.  Visceral fat area, not body mass index, predicts postoperative 30-day morbidity in patients undergoing colon resection for cancer.

Authors:  Benjamin A Kuritzkes; Emmanouil P Pappou; Ravi P Kiran; Onur Baser; Liqiong Fan; Xiaotao Guo; Binsheng Zhao; Stuart Bentley-Hibbert
Journal:  Int J Colorectal Dis       Date:  2018-04-15       Impact factor: 2.571

2.  Is Sarcopenic Obesity an Indicator of Poor Prognosis in Gastric Cancer Surgery? A Cohort Study in a Western Population.

Authors:  V Rodrigues; F Landi; S Castro; R Mast; N Rodríguez; A Gantxegi; J Pradell; M López-Cano; M Armengol
Journal:  J Gastrointest Surg       Date:  2020-07-13       Impact factor: 3.452

3.  Visceral obesity stimulates anaphase bridge formation and spindle assembly checkpoint dysregulation in radioresistant oesophageal adenocarcinoma.

Authors:  A M Mongan; N Lynam-Lennon; R Casey; S Maher; G Pidgeon; J V Reynolds; J O'Sullivan
Journal:  Clin Transl Oncol       Date:  2015-10-16       Impact factor: 3.405

4.  Body composition of the host influences dendritic cell phenotype in patients treated for colorectal cancer.

Authors:  George Malietzis; Gui Han Lee; Hafid O Al-Hassi; David Bernardo; Alexandra I F Blakemore; Robin H Kennedy; Morgan Moorghen; John T Jenkins; Stella C Knight
Journal:  Tumour Biol       Date:  2016-03-10

Review 5.  Clinical Implications of Sarcopenic Obesity in Cancer.

Authors:  Isabella P Carneiro; Vera C Mazurak; Carla M Prado
Journal:  Curr Oncol Rep       Date:  2016-10       Impact factor: 5.075

6.  Parallel Profiles of Inflammatory and Effector Memory T Cells in Visceral Fat and Liver of Obesity-Associated Cancer Patients.

Authors:  Melissa J Conroy; Karen C Galvin; Suzanne L Doyle; Maria E Kavanagh; Ann-Marie Mongan; Aoife Cannon; Gillian Y Moore; John V Reynolds; Joanne Lysaght
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

7.  Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance.

Authors:  Emer M Guinan; S L Doyle; A E Bennett; L O'Neill; J Gannon; J A Elliott; J O'Sullivan; J V Reynolds; J Hussey
Journal:  Support Care Cancer       Date:  2017-12-02       Impact factor: 3.603

8.  CCR1 antagonism attenuates T cell trafficking to omentum and liver in obesity-associated cancer.

Authors:  Melissa J Conroy; Karen C Galvin; Maria E Kavanagh; Ann Marie Mongan; Suzanne L Doyle; Niamh Gilmartin; Cliona O'Farrelly; John V Reynolds; Joanne Lysaght
Journal:  Immunol Cell Biol       Date:  2016-04-05       Impact factor: 5.126

9.  Metabolic Syndrome, as Defined Based on Parameters Including Visceral Fat Area, Predicts Complications After Surgery for Rectal Cancer.

Authors:  Chong-Jun Zhou; Yi-Fan Cheng; Lin-Zhen Xie; Wan-Le Hu; Bo Chen; Lei Xu; Chong-Jie Huang; Mao Cai; Xian Shen; Chang-Bao Liu
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

10.  The Relationship between ECOG-PS, mGPS, BMI/WL Grade and Body Composition and Physical Function in Patients with Advanced Cancer.

Authors:  Ross D Dolan; Louise E Daly; Claribel Pl Simmons; Aoife M Ryan; Wei Mj Sim; Marie Fallon; Derek G Power; Andrew Wilcock; Matthew Maddocks; Michael I Bennett; Caroline Usborne; Barry J Laird; Donald C McMillan
Journal:  Cancers (Basel)       Date:  2020-05-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.